Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
Status:
Withdrawn
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of single doses of NSA-789 on the P50
component of the auditory evoked potentials and to assess the safety, tolerability and the
concentration of NSA-789 in the blood, in nonsmoking patients with schizophrenia.